National Acoustic Laboratories
Macquarie Park, New South Wales, 2113, Australia
NCT Number: NCT07738237
The goal of this clinical trial is to compare two methods of self assessment of hearing with conventional audiometry in an OTC Hearing Aid for adults with perceived mild to moderate hearing loss. The main questions it aims to answer are:
1. To evaluate agreement between prescribed gain outputs generated from conventional audiometry and those generated from the self-assessment response method. 2. Determine whether either self-assessment response method provides acceptable estimated audibility. 3. Evaluate participant preference between the detection response method and the audibility-release response method.
Researchers will compare the two novel methods with conventional audiometry to determine levels of agreement.
Participants will self assess their hearing methods using two novel methods of hearing assessment as well as receive a conventional audiometric evaluation of hearing levels.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Macquarie Park, New South Wales, 2113, Australia
The purpose of this clinical investigation is to evaluate two RH210 hearing aid software self-assessment response methods used to generate NAL-R-based prescribed gain for adults with perceived mild-to-moderate hearing loss. The study will compare prescribed gain outputs derived from each RH210 self-assessment response method with prescribed gain outputs derived from conventional audiometry using the same NAL-R prescription approach. The study will also assess whether the resulting prescribed gain provides estimated audibility using Speech Intelligibility Index (SII) analysis, and will evaluate participant preference between the two self-assessment response methods. The RH210A is an air-conduction hearing aid designed for adults with perceived mild-to-moderate sensorineural hearing loss.
The two RH210 self-assessment response methods evaluated in this study are:
The study is designed to:
This study is not intended to establish Human Factors performance. However, observations arising during execution of the assessment workflow may identify opportunities to improve the user interface, workflow or user guidance before the final Human Factors validation study. These observations are exploratory development outputs and are not formal study endpoints.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Exclusion criteria
-
The Investigational Medical Device (IMD) consists of the RH210 hearing aid software self-test function accessed through the Rehear smartphone application and used in combination with the RH210A compatible in-ear hardware platform.
For this clinical investigation, the RH210A hardware platform is used to present calibrated test sounds (pure tones) to the participant during the app-based self-test. The RH210A is not being evaluated as a diagnostic audiometer, and the study is not designed to evaluate the hearing aid's amplification performance.
The two RH210 self-test response methods evaluated in this study are:
The comparator for this clinical investigation is conventional manual pure-tone audiometry performed in accordance with ANSI/ASA S3.21-2004 (R2023), Methods for Manual Pure-Tone Threshold Audiometry, followed by generation of a NAL-R-based prescribed gain output.
Time frame: Day 1
The primary endpoint is the agreement of NAL-R prescribed gain outputs, by ear and frequency, between:
The frequency-specific analysis will include: 500 Hz; 1 kHz; 2 kHz; and 4 kHz.
The two RH210 response methods are:
Time frame: Day 1
The secondary objective is to evaluate whether RH210 self-test-derived NAL-R prescribed gain outputs provide estimated audibility comparable to the conventional-audiometry-derived NAL-R reference pathway.
The secondary endpoint is the difference in Speech Intelligibility Index / Audibility Index and SRT in quiet between:
Time frame: Day 1
The secondary safety objective is to assess the safety of participant exposure to the RH210 app-based self-test procedure when the RH210A in-ear hardware platform is used to present test sounds.
Safety will be assessed by the incidence, severity, seriousness and relationship to the investigational device or study procedure of:
No formal statistical hypothesis is proposed for safety. Safety outcomes will be summarized descriptively.
Time frame: Day 1
The first exploratory objective is to evaluate participant preference between the two RH210 self-test response methods.
Participant preference will be assessed after completion of both RH210 response methods. The endpoint will include:
Time frame: Day 1
Exploratory endpoints will include, for each response method:
No formal hypothesis is proposed. Results will be summarized descriptively.
Contact information is provided by the study sponsor or research team.
Marisa Poulos, Master of Audiology
CONTACT
Sanna Hou, Master of Audiology
CONTACT
Rehear Audiology Company LTD
Industry
Clinical Evaluation of Two Rehear RH210 Self-Assessment Methods for Generating NAL-R-Based Prescribed Gain Compared With Conventional Audiometry in Adults With Perceived Mild-to-Moderate Hearing Loss
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07081542
Bilateral Hearing Loss, Cochlear Implantation
Kissimmee, Florida, United States
View Trial DetailsNCT00023036
Cytomegalovirus Infection, Cytomegalovirus Infections
Bethesda, Maryland, United States
View Trial DetailsNCT00023049
Deafness, Ear Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07472023
Acoustic Trauma, Ear Diseases
New York, United States
View Trial Details